What anemia panel testing should be performed during pregnancy, including timing and specific laboratory studies such as CBC with red‑cell indices, iron studies, serum folate, vitamin B12, and hemoglobin electrophoresis when indicated?

Anemia Panel Testing in Pregnancy

Screen all pregnant women with a complete blood count (CBC) at the first prenatal visit and again at 28 weeks gestation, using hemoglobin <11 g/dL as the diagnostic threshold for anemia across all trimesters. 1

Universal Screening Approach

Perform CBC with hemoglobin and hematocrit measurement at two key timepoints:

• First prenatal visit (ideally first trimester) 1, 2
• 28 weeks gestation (early third trimester) 1, 3

The CDC and Institute of Medicine recommend screening each trimester, though the strongest consensus supports at minimum the two timepoints above. 4

Diagnostic Threshold

Use hemoglobin <11 g/dL to diagnose anemia in all trimesters and postpartum, regardless of setting or population. 3 This single cutoff simplifies clinical decision-making despite physiologic hemodilution that occurs during pregnancy. 1

Iron Studies: When to Order

Order ferritin testing selectively rather than universally:

• When hemoglobin is <11 g/dL to confirm iron deficiency anemia 5
• Ferritin <30 ng/mL is diagnostic of iron deficiency in pregnancy 5
• Consider ferritin screening in high-risk groups even without anemia (see below) 1

Important caveat: Standard CBC parameters (hemoglobin and MCV) perform poorly as screening tools for iron deficiency. Recent data show that hemoglobin <11 g/dL and MCV <80 fL each detect only 30% of iron deficiency cases (ferritin <30 ng/mL), and more than 50% of women with documented iron deficiency are neither anemic nor microcytic at diagnosis. 6 This limitation underscores why ferritin testing is essential when iron deficiency is suspected clinically.

Additional Laboratory Studies

Red cell indices (MCV, MCH, MCHC) are included in standard CBC and help differentiate microcytic anemia (suggesting iron deficiency or thalassemia) from other causes. 7, 5

Hemoglobin electrophoresis should be performed when:

• MCV is low (<80 fL) but ferritin is normal, suggesting hemoglobinopathy 3
• Patient belongs to high-risk ethnic groups (African, Mediterranean, Southeast Asian, Middle Eastern ancestry) 3
• Family history of hemoglobinopathy exists 3

Serum folate and vitamin B12 testing is not routinely indicated unless macrocytic anemia (MCV >100 fL) is present or there are specific risk factors such as malabsorption, strict vegan diet, or prior bariatric surgery. 8 Folate deficiency causing anemia is rare in settings with food fortification. 8

High-Risk Groups Requiring Closer Monitoring

Intensify surveillance (consider additional screening or earlier ferritin testing) for:

• Non-Hispanic Black and Mexican-American individuals (higher baseline anemia prevalence) 1
• Multiparity (≥2 prior births) 1
• Vegetarian or vegan dietary patterns 1
• Short inter-pregnancy intervals (<18 months) 1
• Gastrointestinal conditions or medications impairing iron absorption (e.g., proton pump inhibitors, antacids) 1
• History of heavy menstrual bleeding or prior anemia 5

Evidence Limitations and Guideline Discordance

A critical tension exists in the evidence base: While multiple organizations recommend universal screening, the USPSTF (2024) concludes that evidence is insufficient to recommend for or against routine screening because no high-quality trials demonstrate that screening and treating iron deficiency anemia improves maternal or infant clinical outcomes (mortality, preterm birth, low birthweight). 9, 4

Despite this evidence gap, screening remains standard practice because:

• Observational data link anemia to adverse outcomes including postpartum hemorrhage, preterm delivery, and low birthweight 3, 8
• Identifying anemia before delivery aids in managing anticipated blood loss, particularly for cesarean delivery or high-risk obstetric scenarios 1
• Iron supplementation reliably improves hematologic parameters (hemoglobin, ferritin), even if downstream clinical benefit is unproven 4
• ACOG, CDC, and FIGO all endorse universal screening despite USPSTF's "insufficient evidence" rating 4, 3, 2

In real-world practice, the consensus favors screening given the low cost and risk of CBC testing, the high prevalence of anemia (affecting 32 million pregnant women globally and 25% in U.S. cohorts), and the potential for severe maternal morbidity from untreated anemia. 3, 7

Practical Testing Algorithm

1. First prenatal visit: Order CBC with differential and red cell indices 1, 2

   • If Hgb <11 g/dL → order ferritin 5
   • If MCV <80 fL with normal ferritin → consider hemoglobin electrophoresis 3
   • If MCV >100 fL → consider folate and B12 testing 8

2. 28 weeks gestation: Repeat CBC 1, 3

   • Reassess using same algorithm as above
   • Note that anemia prevalence increases across trimesters (from 2.8% in first trimester to 40.9% in third trimester in one U.S. cohort) 7

3. High-risk patients: Consider ferritin testing at first visit even if hemoglobin is ≥11 g/dL 1

4. Avoid routine folate/B12 testing unless macrocytosis or specific risk factors are present 8

Common Pitfalls

• Over-reliance on hemoglobin alone: Physiologic hemodilution in pregnancy can mask true anemia or create false-positive diagnoses, especially in the third trimester. 1 Ferritin is the definitive test for iron stores.
• Missing iron deficiency without anemia: More than half of iron-deficient pregnant women are not anemic at diagnosis. 6 Consider ferritin testing in high-risk groups regardless of hemoglobin level.
• Undertesting in third trimester: Only 53.6% of women in one study received third-trimester CBC, missing opportunities to identify worsening anemia before delivery. 7
• Assuming standard prenatal vitamins are sufficient: Prenatal vitamins contain ~30 mg elemental iron, which is inadequate for treating established iron deficiency (requires 60-120 mg daily). 1, 10